| Literature DB >> 26366419 |
P Laudanski1, R Charkiewicz2, A Tolwinska3, J Szamatowicz4, A Charkiewicz5, J Niklinski2.
Abstract
It has been well documented that aberrant expression of selected microRNAs (miRNAs) might contribute to the pathogenesis of disease. The aim of the present study is to compare miRNA expression by the most comprehensive locked-nucleic acid (LNA) miRNA microarray in eutopic endometrium of patients with endometriosis and control. In the study we recruited 21 patients with endometriosis and 25 were disease-free women. The miRNA expression profiles were determined using the LNA miRNA microarray and validated for selected molecules by real-time PCR. We identified 1198 human miRNAs significantly differentially altered in endometriosis versus control samples using false discovery rate of <5%. However only 136 miRNAs showed differential regulation by fold change of at least 1.3. By the use of selected statistical analysis we obtained 45 potential pathways that might play a role in the pathogenesis of endometriosis. We also found that natural killer cell mediated cytotoxicity pathway was found to be inhibited which is consistent with previous studies. There are several pathways that may be potentially dysregulated, due to abnormal miRNA expression, in eutopic endometrium of patients with endometriosis and in this way contribute to its pathogenesis.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26366419 PMCID: PMC4558423 DOI: 10.1155/2015/760698
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Clinical characteristics of patients.
| Endometriosis ( | Control ( | |
|---|---|---|
| Age (years) | 31.35 ± 0.90 | 30.73 ± 0.91 |
| Infertility, | 9 (50) | 16 (64) |
| Primary | 7 | 8 |
| Secondary | 2 | 8 |
| Duration of infertility (months) | 48.2 ± 19.4 (23–71) | 50.8 ± 15.8 (13–71) |
| Ovarian cysts, | ||
| Endometrial | 21 (100) | — |
| Simple | — | 9 (36) |
Data are mean ± SEM. Ranges are provided for “duration of infertility.”
Figure 1Volcano plot for all analyzed human miRNAs. The x-axis (horizontal) is the fold change between endometriosis and control samples (on a log scale, so that up- and downregulation appear symmetric), and y-axis represents the p value for a test of differences between samples (most conveniently on a negative log scale, so smaller p values appear higher up). Red dots represent miRNAs significantly differentially expressed.
Figure 2Heatmap display of significantly expressed miRNAs. Heatmap representation of expression data for miRNAs significantly altered in endometriosis samples compared with control samples (adjusted p value < 0.05). Columns correspond to samples and rows correspond to individual miRNAs. For a given miRNA an average value was computed and subtracted from each observation. The yellow color marks a higher expression (over average expression in two groups), while the blue color represents a lower expression (again with regard to average expression). The color scale represents the magnitude of changes. “s” stands for endometriosis samples and “c” stands for control samples.
Figure 3The figure shows signaling pathways (3: mTOR and 4: VEGF) with marked hypothetical influence of miRNA. The colors present expression of miRNAs assigned to a particular gene. The blue color stands for higher expression in control samples, and the red color stands for higher expression endometriosis. The color scale represents the magnitude of changes. The green arrows represent connections start from transcription factor and which hypothetical expression changes are consistent with hypothetical expression changes of genes regulated by this transcription factor.
Figure 4The figure shows signaling pathways (3: mTOR and 4: VEGF) with marked hypothetical influence of miRNA. The colors present expression of miRNAs assigned to a particular gene. The blue color stands for higher expression in control samples, and the red color stands for higher expression endometriosis. The color scale represents the magnitude of changes. The green arrows represent connections start from transcription factor and which hypothetical expression changes are consistent with hypothetical expression changes of genes regulated by this transcription factor.
Gene ontology (GO) terms overrepresented in eutopic endometrium of patients with endometriosis and control.
| GO term | Adjusted | Adjusted |
|---|---|---|
| Translational elongation | 1 | 0.077 |
|
| ||
| Translational termination | 1 | 0.077 |
|
| ||
| Cotranslational protein targeting to membrane | 1 | 0.077 |
|
| ||
| SRP- (signal-recognition particle-) dependent cotranslational protein targeting to membrane | 1 | 0.077 |
|
| ||
| Protein targeting to endoplasmic reticulum | 1 | 0.077 |
|
| ||
| Protein localization to endoplasmic reticulum | 1 | 0.077 |
|
| ||
| Establishment of protein localization to endoplasmic reticulum | 1 | 0.077 |
The first column contains names of significantly overrepresented GO terms. Both the second and the third columns contain adjusted p values for overrepresentation analysis (Fisher's exact test). The second column presents results for genes associated with miRNA that have higher expression in endometriosis (of at least 20%) and the third column presents results for genes associated with miRNA that present higher expression in control samples (of at least 20%). GO terms with adjusted p values <0.25 were recognized as significantly overrepresented.
Signaling Pathway Impact Analysis (SPIA) showing perturbation of signaling pathways in eutopic endometrium of patients with endometriosis versus control.
| The name of the pathway | Adjusted | Status |
|---|---|---|
| Alcoholism | 0 | A |
| Olfactory_transduction | 0 | A |
| Viral_carcinogenesis | 0 | I |
| Systemic_lupus_erythematosus | 0.01 | A |
| Chronic_myeloid_leukemia | 0.01 | A |
| Cytosolic_DNA-sensing_pathway | 0.01 | A |
| Natural_killer_cell_mediated_cytotoxicity | 0.01 | I |
| RNA_transport | 0.03 | I |
| Neurotrophin_signaling_pathway | 0.04 | A |
The first column shows names of significantly impacted pathways, the second column contains adjusted p values, and the third shows type of impact [activation (A)/inhibition (I)] in the analyzed group of samples with reference to the control group.
Relative quantity (RQ) values of selected miRNA as validated by real-time PCR in patients with endometriosis (n = 42) and control (n = 25).
| Number | miRNA | Endometriosis | Control |
| Fold change difference between endometriosis and control by miRNA microarrays |
|---|---|---|---|---|---|
| 1 | miR-4454 | 0.34 (0.07–2.07) | 0.41 (0.14–3.5) | 0.34 | 1.51 |
| 2 | miR-4714-5p | 0.63 (0.05–9.9) | 0.9 (0.01–4) | 0.9 | 1.86 |
| 3 | miR-5193 | 0.29 (0.04–11.3) | 0.51 (0.04–22.9) | 0.13 | 1.93 |
| 4 | miR-4284 | 1.88 (0.1–10.3) | 1.6 (0.2–15.7) | 0.83 | 2.28 |
| 5 | miR-5187-3p | 0.28 (0.05–3.2) | 0.20 (0.07–0.69) | 0.051 | 1.41 |
| 6 | miR-3680-5p | 0.8 (0.07–31.6) | 1.2 (0.06–11.2) | 0.96 | 2.21 |
| 7 | miR-3667-5p | 0.68 (0.06–18.19) | 1.8 (0.07–8.5) | 0.63 | 2.3 |
| 8 | miR-3152-5p | 0.17 (0.03–1.4) | 0.27 (0.002–2.8) | 0.048 | 1.44 |
| 9 | miR-23a-3p | 1.22 (0.02–11.3) | 1.17 (0.03–12.3) | 0.48 | 1.55 |
| 10 | miR-23b-3p | 0.4 (0.06–1.7) | 0.5 (0.1–2.2) | 0.44 | 2.08 |
| 11 | miR-30d-5p | 0.22 (0.05–21) | 0.42 (0.1–40) | 0.05 | 1.37 |